Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07389642

Brain Oligometastasis in NSCLC

75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in such disease presentation. We will analyze the impact of different therapeutic strategies on patients treated at Bordeaux University Hospital and the Bergonié Institute

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Brain Oligometastatic Brain Diseases Brain Neoplasms Bronchial Neoplasms Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Central Nervous System Diseases Central Nervous System Neoplasms Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Nervous System Diseases Nervous System Neoplasms Non-small Cell Lung Cancer Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU de Bordeaux

Bordeaux, France

About this study

75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in terms of disease control: local treatment of the main tumor and brain versus systemic treatment with chemotherapy and immunotherapy. We will analyze the impact of these 2 strategies on patients treated at Bordeaux University Hospital and the Bergonié Institute.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Consecutive patients managed at Bordeaux University Hospital
  • Non-small-cell lung cancer
  • Oligometastatic brain cancer (fewer than 5 lesions at diagnosis)
  • Patient over 18 years old

Exclusion criteria

  • Oncogenic addiction EGFR, ALK, ROS1
  • Patient with concomitant cancer
  • Patient with prior treatment for lung cancer in the year preceding diagnosis at metastatic stage

Treatment and study plan

Standard treatments / multiple strategies

Other

Standard treatments / multiple strategies

Primary outcomes

  1. Progression free survival (PFS)

    Time frame: Once, at progression or death from any cause

    Time from random assignment in a clinical trial to disease progression or death from any cause

Secondary outcomes

  1. PFS from the date of the next treatment to disease progression or death from any cause (PFS2)

    Time frame: Once, at progression or death from any cause

    PFS from the date of the next treatment to disease progression or death from any cause

  2. Overall survival (OS)

    Time frame: Once, death from any cause or lost of follow-up

    Time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive

Sponsors and collaborators

Lead sponsor

University Hospital, Bordeaux

Other

Registry information

Official study title

Management of Patients With Brain-onset Oligometastatic Non-small-cell Lung Cancer (NSCLC)

Acronym: OligoLung

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Feb 5, 2026
Registry last updated
Feb 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.